Cutting OTLK, 7% Loss. Should Have Went 1/2 on Small SizeBad idea. Should have cut earlierby InteractiveSwingTradingUpdated 4
Looks Good at $1.00. Medium Size, Entry 3/4I said to myself I would buy only at $1.00. I've been watching this for awhile now. Short term swingLongby InteractiveSwingTrading3
Get Out Of This One, Don't Like The Way It's ActingWait for 1 dollar or nothing at allby InteractiveSwingTrading1
Looks Like a Nice Little GambleSimilar to the IGC play. Has some followers, and there hasn't been any news for awhile. 1/2 entryLongby InteractiveSwingTrading2
Oppenheimer analyst Leland Gershell outperform rating and $12www.marketwatch.com finance.yahoo.com www.marketwatch.com seekingalpha.com by AlenCiken1
$OTLK THIS IS JUST THE BEGINNING FOR OUTLOOK THERAPEUTICSIf you are not familiar with the Stock, get to know it now, it has made investors a lot of money in the past 4 trading days, tripling in value. There is always concerns when it comes to such low cap companies but this rally is based on facts not speculation. After a extremely upbeat drug trial report it was upgraded to $12 the following day by Oppenheimer. There is no need to worry about missing out on this rally as it has a very long way to g, it was 70% higher on Feb 18th. A nice entry level is $3.50 just above resistance, with a take profit at $6 below the 200MA. Average Analysts price target $7 Average Analysts rating BUY Company Description Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.Longby RedHotStocks6
$OTLK Outlook Therapeutics up 12% premarket, loads more to come.This was a real winner yesterday and today is going to be the same, already up 12% pre market, we think there should be continuation in this name for days to come. Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer OUTLOOK THERAPEUTICS INC. Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. Longby DEXWireNews7
Bullish Formation (Opportunity) - Weekly Position - OTLKHello Successful Traders, The stock (OTLK) manifests the opportunity of a bullish upside, considering the previous con-test (and infiltration) for an all time low. A correction is a viable observation, considering the current reverse stop split (limiting the amount of stocks prevalent) there may increased demand (resulting in price spike). Await for confirmation prior to entering market. (1.65 - 2.00) Resistance Level 2 - (30.00 - 30.60) 60 cent interval Resistance Level 1 - (18.10 - 18.65) 55 cent interval Key Price Zone (KPZ) - (10.50 - 11.05) 55 cent interval Support Level 1 - (1.00 - 1.60) 60 cent interval Furthermore, there appears to be an "underwritten public offering of 10,340,000 shares of its common stock" (Yahoo Finance). Not Investment Advice. For Educational and Analytical Purposes Only. (Be COnscientious and Stick To Your Trading Itinerary)*** -LionGateLongby LionGate2